Tilomisole
 | |
| Names | |
|---|---|
| IUPAC name
[3-(4-Chlorophenyl)[1,3]thiazolo[3,2-a]benzimidazol-2-yl]acetic acid | |
| Identifiers | |
| 58433-11-7 | |
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL2104737 |
| ChemSpider | 38987 |
| KEGG | D06148 |
| PubChem | 42747 |
| UNII | 651G60U372  |
| |
| |
| Properties | |
| C17H11ClN2O2S | |
| Molar mass | 342.80 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tilomisole (WY-18,251) is an experimental drug which acts as an immunomodulator and has been studied for the treatment of some forms of cancer.[1][2]
References
- ↑ Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ (1980). "Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633)". Journal of Immunopharmacology. 2 (4): 491–508. PMID 6970786.
- ↑ Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R (March 1992). "WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients". Molecular Biotherapy. 4 (1): 10–4. PMID 1385709.
This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.